Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2024 · View financials
Decision snapshot: ACAD stock price vs DFS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DFS's multiple
Needs DFS P/E.
Implied fair value · at ACAD's multiple
Needs ACAD P/E.
Price unavailable
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability edge
Asset efficiency edge
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: ACAD FY 2025 (ended Dec 31, 2025) · DFS FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity
$1.23B
Price / tangible book
—
Price / book
—
Return on equity
31.9%
Return on assets
25.0%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity
$17.58B
Price / tangible book
—
Price / book
—
Return on equity
25.3%
Return on assets
3.1%
Efficiency ratio
36.7%
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
ACADIA PHARMACEUTICALS INC. · implied price per share
Bear
$5.79
Base
$6.81
Bull
$7.83
DISCOVER FINANCIAL SERVICES · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.00x
0.91x
Net debt / EBITDA
Leverage against operating earnings
-1.51x
-0.40x
Cash and equivalents
Liquid reserves on the balance sheet
$227.76M
$23.10B
Total debt
Interest-bearing obligations outstanding
$32.00K
$16.37B
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ACAD vs SUPN
Sage Therapeutics, Inc.
ACAD vs SAGE
Jazz Pharmaceuticals plc
ACAD vs JAZZ
Alkermes plc.
ACAD vs ALKS
Harmony Biosciences Holdings, Inc.
ACAD vs HRMY
Krystal Biotech, Inc.
ACAD vs KRYS
CAPITAL ONE FINANCIAL CORP
ACAD vs COF
American Express Company
ACAD vs AXP
Visa Inc.
ACAD vs V
Mastercard Incorporated
ACAD vs MA
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Price unavailable
